DK1210951T3 - Præparat indeholdende östrogen-agonister/antagonister og testosteron til behandling af et fald i niveauet af hormonet testosteron - Google Patents

Præparat indeholdende östrogen-agonister/antagonister og testosteron til behandling af et fald i niveauet af hormonet testosteron

Info

Publication number
DK1210951T3
DK1210951T3 DK01309457T DK01309457T DK1210951T3 DK 1210951 T3 DK1210951 T3 DK 1210951T3 DK 01309457 T DK01309457 T DK 01309457T DK 01309457 T DK01309457 T DK 01309457T DK 1210951 T3 DK1210951 T3 DK 1210951T3
Authority
DK
Denmark
Prior art keywords
testosterone
antagonists
treat
decrease
level
Prior art date
Application number
DK01309457T
Other languages
Danish (da)
English (en)
Inventor
David Burton Mclean
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Application granted granted Critical
Publication of DK1210951T3 publication Critical patent/DK1210951T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK01309457T 2000-11-30 2001-11-08 Præparat indeholdende östrogen-agonister/antagonister og testosteron til behandling af et fald i niveauet af hormonet testosteron DK1210951T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25007100P 2000-11-30 2000-11-30
EP01309457A EP1210951B1 (fr) 2000-11-30 2001-11-08 Composition contenant des agoniste-antagonistes d'oestrogène et de la testostérone pour le traitement d' une réduction des taux de l'hormone testostérone

Publications (1)

Publication Number Publication Date
DK1210951T3 true DK1210951T3 (da) 2005-03-29

Family

ID=22946195

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01309457T DK1210951T3 (da) 2000-11-30 2001-11-08 Præparat indeholdende östrogen-agonister/antagonister og testosteron til behandling af et fald i niveauet af hormonet testosteron

Country Status (15)

Country Link
US (2) US20020115676A1 (fr)
EP (1) EP1210951B1 (fr)
JP (1) JP2002193809A (fr)
KR (1) KR20020042505A (fr)
AT (1) ATE288303T1 (fr)
AU (1) AU779964B2 (fr)
CA (1) CA2363935A1 (fr)
DE (1) DE60108710T2 (fr)
DK (1) DK1210951T3 (fr)
ES (1) ES2233570T3 (fr)
HU (1) HUP0105201A3 (fr)
IL (1) IL146701A0 (fr)
NZ (1) NZ515822A (fr)
PT (1) PT1210951E (fr)
ZA (1) ZA200109836B (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8496960B2 (en) * 2001-10-23 2013-07-30 Purdue Pharma L.P. Terazosin transdermal device and methods
US20040214898A1 (en) * 2001-11-29 2004-10-28 Steiner Mitchell S. Methods for treating hot flashes
US20060269611A1 (en) * 2001-11-29 2006-11-30 Steiner Mitchell S Prevention and treatment of androgen-deprivation induced osteoporosis
US20050080143A1 (en) * 2001-11-29 2005-04-14 Steiner Mitchell S. Treatment of androgen-deprivation induced osteoporosis
US20080249183A1 (en) * 2001-11-29 2008-10-09 Steiner Mitchell S Treatment of androgen-deprivation induced osteoporosis
US20070197664A1 (en) * 2001-11-29 2007-08-23 Steiner Mitchell S Prevention and treatment of androgen-deprivation induced osteoporosis
WO2004054557A2 (fr) * 2002-12-18 2004-07-01 Laboratoires Besins International Traitement de la mastalgie a l'aide de 4-hydroxy tamoxifene
TWI330529B (en) * 2003-01-13 2010-09-21 Horphag Res Luxembourg Holding Sa A preparation for improving sperm quality or fertility,a kit comprising the same and uses thereof
KR101180896B1 (ko) * 2003-05-05 2012-09-07 벤-구리온 유니버시티 오브 더 네게브 리서치 앤드 디벨럽먼트 어쏘러티 주사용 가교결합된 폴리머 제제 및 그의 용도
PL1694319T3 (pl) * 2003-12-15 2009-01-30 Besins Healthcare Lu Sarl Zastosowanie 4-hydroksytamoksyfenu do wytwarzania leku do leczenia ginekomastii
EP1550440A1 (fr) * 2003-12-15 2005-07-06 Laboratoires Besins International Utilisation du 4-hydroxytamoxifen pour la préparation d'un médicament pour le traitement de la gynécomastie
US7968532B2 (en) * 2003-12-15 2011-06-28 Besins Healthcare Luxembourg Treatment of gynecomastia with 4-hydroxy tamoxifen
WO2005066337A2 (fr) * 2004-01-09 2005-07-21 Yissum Research Development Company Of The Hebrew University Of Jerusalem Composes, compositions pharmaceutiques et procedes therapeutiques pour prevenir et traiter des maladies et des troubles associes a la formation de fibrilles amyloides
EP2307026B1 (fr) 2008-07-04 2016-04-13 The Heart Research Institute Limited Utilisation d'androgènes pour une régénérescence vasculaire et une réparation endothéliale
KR102335267B1 (ko) * 2017-03-16 2021-12-06 주식회사 자연과학기술 무지개송어 정소로부터 테스토스테론의 추출방법
US20240000799A1 (en) * 2020-12-04 2024-01-04 Lennham Pharmaceuticals, Inc. Deuterated forms of testosterone and methods of use

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US585905A (en) * 1897-07-06 Frank bonileor
US5391557A (en) * 1993-10-15 1995-02-21 Eli Lilly And Company Methods for the treatment of peri-menopausal syndrome
US5589482A (en) * 1994-12-14 1996-12-31 Pfizer Inc. Benzo-thiophene estrogen agonists to treat prostatic hyperplasia
US5552412A (en) * 1995-01-09 1996-09-03 Pfizer Inc 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis
IL120262A (en) * 1996-02-28 2001-01-28 Pfizer Droloxifene and derivatives thereof for use in increasing serum testosterone levels
HN1996000101A (es) * 1996-02-28 1997-06-26 Inc Pfizer Terapia combinada para la osteoporosis
DE19610635A1 (de) * 1996-03-11 1997-09-18 Schering Ag Sequentielle Estrogen/Progesteronantagonist-Kombination für die Hormonersatz-Therapie
DE19619045C1 (de) * 1996-05-02 1997-11-13 Jenapharm Gmbh Verwendung von Kombinationspräparaten zur Behandlung hypogonadaler Männer sowie Männern mit Hypophysenerkrankungen
US6653297B1 (en) * 1997-07-03 2003-11-25 Medical College Of Hampton Roads Control of selective estrogen receptor modulators
DE19825591A1 (de) * 1998-06-09 1999-12-23 Jenapharm Gmbh Pharmazeutische Kombinationen zum Ausgleich eines Testosteron-Defizits beim Mann mit gleichzeitigem Schutz der Prostata

Also Published As

Publication number Publication date
ATE288303T1 (de) 2005-02-15
ZA200109836B (en) 2003-05-29
US20020115676A1 (en) 2002-08-22
HUP0105201A2 (hu) 2002-12-28
IL146701A0 (en) 2002-07-25
HU0105201D0 (en) 2002-01-28
CA2363935A1 (fr) 2002-05-30
EP1210951A3 (fr) 2003-09-24
EP1210951A2 (fr) 2002-06-05
DE60108710T2 (de) 2006-05-04
AU9516501A (en) 2002-06-06
AU779964B2 (en) 2005-02-24
ES2233570T3 (es) 2005-06-16
EP1210951B1 (fr) 2005-02-02
KR20020042505A (ko) 2002-06-05
NZ515822A (en) 2003-05-30
HUP0105201A3 (en) 2004-04-28
US20050288325A1 (en) 2005-12-29
PT1210951E (pt) 2005-04-29
DE60108710D1 (de) 2005-03-10
JP2002193809A (ja) 2002-07-10

Similar Documents

Publication Publication Date Title
DK1210951T3 (da) Præparat indeholdende östrogen-agonister/antagonister og testosteron til behandling af et fald i niveauet af hormonet testosteron
DK1199069T3 (da) Anvendelse af en estrogenagonist/-antagonist til forbedring eller bibeholdelse af urogenital sundhed
MY136097A (en) Methods for treating osteoarthritis using an estrogen agonist/antagonist
CY1111049T1 (el) Συσκευη για αναμιξη και παροχη οστικου τσιμεντου
NO20024221D0 (no) Blandinger inneholdende alfa-2-adrenerge agonistkomponenter
DK1135153T3 (da) Anvendelser af EPH-receptorantagonister og -agonister til behandling af vaskulære forstyrrelser
DE60033541D1 (de) Werkzeug zur stabilisierung von knochenstrukturen
DK1379224T3 (da) Guanylat-cyclase receptor-agonister til behandling af vævsinflammation og carciogenese
EE200300246A (et) EP4 retseptori suhtes selektiivsed agonistid osteoporoosi raviks
MXPA05006629A (es) Formas de dosificacion que contienen un inhibidor de bomba de protones, un nsaid y un amortiguador.
IS6388A (is) EP4 viðtaka valvís gerandefni í meðhöndluninni á beingisnun
DK1117403T3 (da) MGLUR5-antagonister til behandling af smerte og angst
ATE406159T1 (de) Behandlung von hyperlipidämie
CL2004000026A1 (es) Uso de una composicion que comprende 0 a alrededor de 29% de cis-clomifeno y de alrededor de 100 a alrededor de 71% de trans-clomifeno para preparar un medicamento util para aumentar los niveles de testosterona en suero en un mamifero masculino.
DE69911023D1 (de) Antagonisten des gonadotropin freisetzenden hormons
DK1272897T3 (da) Adenosin-A2A-receptorantagonister til behandling og forebyggelse af leverfibrose, cirrose og fedtlever
UY27203A1 (es) Bencimidazoles útiles en el tratamiento de la disfunción sexual
DK1131083T3 (da) Anvendelse af væksthormonfrigørende forbindelser og antagonister deraf til behandling af tumorer
DK1467762T3 (da) Anvendelse af en H1-antagonist og rimexolon som et sikkert steroid til behandling af rhinitis
MXPA05011410A (es) Tratamiento de incontinencia con agonistas de 5htc2.
DE60112982D1 (de) Einrichtung zur Bereitstellung von Server-Inhalten
NO20034165L (no) Forankringshylse for injeksjonsfiksering
ATE373800T1 (de) Vorrichtung zur lichtmischung
DK1420789T3 (da) Anvendelse af aktivstoffer med my-opioid-receptoragonistisk virkning og opioid-receptorantagonistisk virkning som kombinationslægemidler til cancerbehandling
EA200200839A1 (ru) Композиции с контролируемым высвобождением, содержащие агонист и антагонист опиоидов